Clinical Outcomes in Patients With FLT3-ITD –Mutated Relapsed/Refractory Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplant After Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial

Patients with fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) relapsed or refractory (R/R) acute myeloid leukemia (AML) have a dismal prognosis and limited effective treatment options outside of clinical trials [1-3]. In patients with R/R AML, performing a hematopoietic stem cell transplant (HSCT) after first salvage therapy decreases the risk of relapse and improves relapse-free survival (RFS) and overall survival (OS) probabilities [4]. Traditional cytotoxic salvage chemotherapy has been largely ineffective in controlling FLT3-ITD R/R disease, enabling ≤ 20% of patients to proceed to HSCT [5,6].

Source: Biology of Blood and Marrow Transplantation - October 1, 2020 Category: Hematology Authors: Siddhartha Ganguly, Jorge E. Cortes, Alwin Kr ämer, Mark J. Levis, Giovanni Martinelli, Alexander E. Perl, Nigel H. Russell, Meena Arunachalam, Cedric Dos Santos, Guy Gammon, Arnaud Lesegretain, Derek E. Mires, Hoang Pham, Yibin Wang, Samer K. Khaled Source Type: research